Compare PDEX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDEX | TNXP |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.4M | 199.7M |
| IPO Year | 1995 | 2008 |
| Metric | PDEX | TNXP |
|---|---|---|
| Price | $72.89 | $10.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $56.00 | N/A |
| AVG Volume (30 Days) | 62.5K | ★ 413.4K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.31 | ★ 91.75 |
| EPS | ★ 4.12 | N/A |
| Revenue | ★ $77,548,000.00 | $13,107,000.00 |
| Revenue This Year | $7.22 | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $17.60 | ★ N/A |
| Revenue Growth | 16.45 | ★ 29.85 |
| 52 Week Low | $23.52 | $9.40 |
| 52 Week High | $77.00 | $25.69 |
| Indicator | PDEX | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 33.24 |
| Support Level | $56.35 | $10.03 |
| Resistance Level | $77.00 | $12.99 |
| Average True Range (ATR) | 4.29 | 0.55 |
| MACD | 0.90 | -0.28 |
| Stochastic Oscillator | 78.30 | 10.01 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.